Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Post time 2023-7-24 22:06:04

journal：European Journal of Cancer

Authors：E. Livingstone; H. Gogas; L. Kandolf-Sekulovic; F. Meier; T.K. Eigentler; M. Ziemer; P.A.M. Terheyden; A.H. Gesierich; R.A. Herbst; K.C. K?hler; D.C. Ziogas; Z. Mijuskovic; M. Garzarolli; C. Garbe; A. Roesch; S. Ugurel; R. Gutzmer; J.J. Grob; F. Kiecker; J. Utikal; C. Windemuth-Kieselbach; S. Eckhardt; L. Zimmer; D. Schadendorf

Published date：2023-9-

DOI：10.1016/j.ejca.2023.112941

PDF link：https://www.sciencedirect.com/sc ... 959804923002903/pdf

Article link：http://dx.doi.org/10.1016/j.ejca.2023.112941

Article Source：Elsevier BV

Post time 2023-7-24 22:06:05

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-7-24 22:07:16

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-7-24 22:08:15

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-7-24 22:08:36

: This post has been completed
Completed attachments will be deleted within 24 hours.

Post time 2023-7-25 10:59:33

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Best Answer

Same Category

Latest Reply

Announcement

Enthusiastic users today